Esmo 2020 preview – a kidney cancer showdown gets star billing
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
Cut-price drug venture takes aim at Pfizer and Astrazeneca
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
Tecentriq’s ovarian failure highlights a changing market
An Avastin combination draws a blank in the Imagyn-050 study. Will a combo with a Parp inhibitor fare any better?
US FDA approval tracker: several early decisions in May
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
Careful label reading reveals more Lynparza doubts
Close analysis of the Parp inhibitor’s pivotal prostate cancer trial raises additional questions over this week’s US approval.
Lynparza’s prostate cancer surprise
An unexpectedly broad prostate cancer label gives the Parp inhibitor a strong advantage over Clovis’s rival Rubraca.
Go or no go? Oncology dominates upcoming decisions
Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.
